[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100433427":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":50,"collaborators":20,"id":53,"slug":20,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Manitoba","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Embolization of Middle Meningeal Artery for Subdural Hematoma","EXPERIMENTAL","All patients with CSDH will undergo embolization of Middle Meningeal artery",[13],"Procedure: Embolization of the middle meningeal artery",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Embolization of the middle meningeal artery","embolization of the middle meningeal artery with an embolic agent (Microparticles, liquid embolic agents, SwiftPAC coils or others).",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Jai Shankar, MD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","4313734164","shivajai1@gmail.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Susan Alcock, RN","2047893669","susan.alcock@umanitoba.ca",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":20,"geoPoint":20,"contacts":42},"Health Sciences centre","RECRUITING","Winnipeg MB","Manitoba","R3A 1R9","Canada",[43,46,49],{"name":44,"role":27,"phone":45,"phoneExt":20,"email":29},"Jai Shankar, MD FRCPC","431 373 4164",{"name":47,"role":27,"phone":48,"phoneExt":20,"email":33},"Susan Alcock","204 789 3996",{"name":44,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Jai Shankar","Professor","100433427",false,"NCT04923984","Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)","Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada -EMMA-Can","EMMA-Can","Inclusion Criteria:\n\n\\- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.\n\nExclusion Criteria:\n\n* If informed consent cannot be obtained from the patient or their substitute decision maker.\n* Known allergy to liquid embolic agent","ALL","18 Years",{"count":63,"type":64},1000,"ESTIMATED","INTERVENTIONAL",[67],"NA","EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH.\n\nHypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.",[70],"Subdural Hematoma",[72,73,74],"Embolization","Middle Meningeal Artery","Chronic Subdural Hematoma","2026-02-02",{"date":77,"type":78},"2026-02-03","ACTUAL",{"date":80,"type":78},"2021-05-01",{"date":82,"type":64},"2029-12-31",{"name":5,"class":6},1]